PURPOSE: To evaluate late urinary function after permanent prostate brachytherapy using a validated, patient-administered quality-of-life instrument. METHODS AND MATERIALS: A total of 225 consecutive patients underwent prostate brachytherapy between April 1995 and March 1998. Of the 225 patients, 17 had died and 3 had been institutionalized secondary to Alzheimer's disease. Of the remaining 205 patients, each was mailed a self-administered questionnaire (the urinary function component of the Expanded Prostate Cancer Index [EPIC] and the International Prostate Symptom Score [IPSS]). Of the 205 surveys mailed, 195 (95.1%) were returned. The mean and median follow-up was 66.3 and 64.0 months, respectively. The clinical parameters evaluated included age, pretreatment prostate-specific antigen level, Gleason score, stage, risk group, prostate volume, presence of diabetes and hypertension, and tobacco consumption. The treatment parameters included the ultrasound planning volume, hormonal status, use of supplemental external beam radiotherapy, isotope, and follow-up. The dosimetric parameters included values of the minimal dose received by 90% of the prostate gland and the percentage of prostate volume receiving 100%, 150%, and 200% of the prescribed minimal peripheral dose. Because detailed baseline urinary function was not available, a cross-sectional survey was performed in which 51 newly diagnosed prostate cancer patients of comparable demographics served as controls. RESULTS: When the survey scores for the implant patients were compared with the control group, no significant differences in either the IPSS or function, bother, incontinence, or irritation/obstruction subscales of the urinary EPIC were discernible. In addition, no significant difference was observed between the implant and control groups when the EPIC and IPSS surveys were evaluated by each individual question. Of all the evaluated parameters, the use of tobacco was the best predictive variable for diminished quality of life. CONCLUSION: No significant difference was noted in the overall long-term urinary quality of life when brachytherapy patients were compared with a group of newly diagnosed prostate cancer patients of comparable demographics. Of all parameters evaluated, tobacco consumption was the single strongest predictor of late urinary function.
PURPOSE: To evaluate late urinary function after permanent prostate brachytherapy using a validated, patient-administered quality-of-life instrument. METHODS AND MATERIALS: A total of 225 consecutive patients underwent prostate brachytherapy between April 1995 and March 1998. Of the 225 patients, 17 had died and 3 had been institutionalized secondary to Alzheimer's disease. Of the remaining 205 patients, each was mailed a self-administered questionnaire (the urinary function component of the Expanded Prostate Cancer Index [EPIC] and the International Prostate Symptom Score [IPSS]). Of the 205 surveys mailed, 195 (95.1%) were returned. The mean and median follow-up was 66.3 and 64.0 months, respectively. The clinical parameters evaluated included age, pretreatment prostate-specific antigen level, Gleason score, stage, risk group, prostate volume, presence of diabetes and hypertension, and tobacco consumption. The treatment parameters included the ultrasound planning volume, hormonal status, use of supplemental external beam radiotherapy, isotope, and follow-up. The dosimetric parameters included values of the minimal dose received by 90% of the prostate gland and the percentage of prostate volume receiving 100%, 150%, and 200% of the prescribed minimal peripheral dose. Because detailed baseline urinary function was not available, a cross-sectional survey was performed in which 51 newly diagnosed prostate cancerpatients of comparable demographics served as controls. RESULTS: When the survey scores for the implant patients were compared with the control group, no significant differences in either the IPSS or function, bother, incontinence, or irritation/obstruction subscales of the urinary EPIC were discernible. In addition, no significant difference was observed between the implant and control groups when the EPIC and IPSS surveys were evaluated by each individual question. Of all the evaluated parameters, the use of tobacco was the best predictive variable for diminished quality of life. CONCLUSION: No significant difference was noted in the overall long-term urinary quality of life when brachytherapy patients were compared with a group of newly diagnosed prostate cancerpatients of comparable demographics. Of all parameters evaluated, tobacco consumption was the single strongest predictor of late urinary function.
Authors: Peter Chang; Meredith M Regan; Montserrat Ferrer; Ferran Guedea; Dattatraya Patil; John T Wei; Larry A Hembroff; Jeff M Michalski; Chris S Saigal; Mark S Litwin; Daniel A Hamstra; Irving D Kaplan; Jay P Ciezki; Eric A Klein; Adam S Kibel; Howard M Sandler; Rodney L Dunn; Catrina M Crociani; Martin G Sanda Journal: J Urol Date: 2016-09-02 Impact factor: 7.450
Authors: Thomas N Eade; Eric M Horwitz; Karen Ruth; Mark K Buyyounouski; David J D'Ambrosio; Steven J Feigenberg; David Y T Chen; Alan Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2008-01-22 Impact factor: 7.038
Authors: Nicole L Simone; Cynthia Ménard; Benjamin P Soule; Paul S Albert; Peter Guion; Sharon Smith; Denise Godette; Nancy S Crouse; Linda C Sciuto; Theresa Cooley-Zgela; Kevin Camphausen; C Norman Coleman; Anurag K Singh Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-12 Impact factor: 7.038
Authors: Michael Pinkawa; Marc D Piroth; Branka Asadpour; Bernd Gagel; Karin Fischedick; Jaroslav Siluschek; Mareike Kehl; Barbara Krenkel; Michael J Eble Journal: Strahlenther Onkol Date: 2009-02-25 Impact factor: 3.621
Authors: Michael Pinkawa; Karin Fischedick; Bernd Gagel; Marc D Piroth; Branka Asadpour; Jens Klotz; Holger Borchers; Gerhard Jakse; Michael J Eble Journal: BMC Cancer Date: 2009-08-24 Impact factor: 4.430